[go: up one dir, main page]

WO2003013585A8 - Mifaxin agonists and antagonists for use in the treatment of metabolic - Google Patents

Mifaxin agonists and antagonists for use in the treatment of metabolic

Info

Publication number
WO2003013585A8
WO2003013585A8 PCT/IB2002/003545 IB0203545W WO03013585A8 WO 2003013585 A8 WO2003013585 A8 WO 2003013585A8 IB 0203545 W IB0203545 W IB 0203545W WO 03013585 A8 WO03013585 A8 WO 03013585A8
Authority
WO
WIPO (PCT)
Prior art keywords
mifaxin
agonists
antagonists
activity
metabolic
Prior art date
Application number
PCT/IB2002/003545
Other languages
French (fr)
Other versions
WO2003013585A1 (en
Inventor
John Lucas
Deno Dialynas
Kristen Briggs
Aaron Scalia
Original Assignee
Genset Sa
John Lucas
Deno Dialynas
Kristen Briggs
Aaron Scalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, John Lucas, Deno Dialynas, Kristen Briggs, Aaron Scalia filed Critical Genset Sa
Publication of WO2003013585A1 publication Critical patent/WO2003013585A1/en
Publication of WO2003013585A8 publication Critical patent/WO2003013585A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of MIFAXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
PCT/IB2002/003545 2001-08-08 2002-08-06 Mifaxin agonists and antagonists for use in the treatment of metabolic WO2003013585A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31151001P 2001-08-08 2001-08-08
US60/311,510 2001-08-08

Publications (2)

Publication Number Publication Date
WO2003013585A1 WO2003013585A1 (en) 2003-02-20
WO2003013585A8 true WO2003013585A8 (en) 2003-04-17

Family

ID=23207219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003545 WO2003013585A1 (en) 2001-08-08 2002-08-06 Mifaxin agonists and antagonists for use in the treatment of metabolic

Country Status (1)

Country Link
WO (1) WO2003013585A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3538711B2 (en) * 1997-10-29 2004-06-14 大塚製薬株式会社 Smooth muscle proliferation inhibitory composition, arteriosclerosis diagnostic method and kit
JP2003527067A (en) * 1998-05-21 2003-09-16 スミスクライン ビーチャム コーポレーション ACRP30R1L, a homologue of ACRP30 (30 KD adipocyte complement-related protein)
WO2000056862A1 (en) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
AU5129800A (en) * 1999-05-11 2000-11-21 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
JP2003501028A (en) * 1999-05-27 2003-01-14 ザイモジェネティクス，インコーポレイティド Adipocyte complement-related protein homolog zacrp7
AU785090B2 (en) * 2000-01-14 2006-09-14 Serono Genetics Institute S.A. OBG3 globular head and uses thereof for decreasing body mass

Also Published As

Publication number Publication date
WO2003013585A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
HUS1600042I1 (en) Therapeutic use of anti-CS1 antibodies
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
WO2004047760A3 (en) Novel chemical compounds
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
BR0315598A (en) Neutralizing antibodies to gdf-8 and their uses
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2005030240A3 (en) Vege-cor vege-d materials and methods for stimulation of neural stem cells
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
PL378026A1 (en) Treatment of diseases with alpha-7 nach receptor full agonists
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU2003299378A1 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2001092330A3 (en) Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
WO2006047759A3 (en) Kinase inhibitors for the treatment of diabetes and obesity
WO2003013578A8 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2003237397A1 (en) Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
WO2003101953A3 (en) Triazaspiro compounds useful for treating or preventing pain
WO2003013585A8 (en) Mifaxin agonists and antagonists for use in the treatment of metabolic
WO2003013604A3 (en) Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2005070042A3 (en) Novel chemical compounds
WO2007067516A3 (en) Multiple myeloma
WO2004076414A3 (en) Novel compounds
WO2003095485A3 (en) Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
WO2003030936A1 (en) Remedies for life style-related diseases or cibophobia and method of screening the same
WO2003033534A3 (en) Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP